Published in Int J Radiat Oncol Biol Phys on March 01, 2010
Novel assessment of renal motion in children as measured via four-dimensional computed tomography. Int J Radiat Oncol Biol Phys (2011) 1.02
Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile. Health Phys (2015) 0.91
Mitigation of Lethal Radiation Syndrome in Mice by Intramuscular Injection of 3D Cultured Adherent Human Placental Stromal Cells. PLoS One (2013) 0.88
An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy. Radiat Oncol (2013) 0.84
Bilateral kidney preservation by volumetric-modulated arc therapy (RapidArc) compared to conventional radiation therapy (3D-CRT) in pancreatic and bile duct malignancies. Radiat Oncol (2011) 0.84
Comparison of the dosimetries of 3-dimensions Radiotherapy (3D-RT) with linear accelerator and intensity modulated radiotherapy (IMRT) with helical tomotherapy in children irradiated for neuroblastoma. BMC Med Phys (2012) 0.83
The advantage of 3D conformal treatment of lumbar spine metastases in comparison to traditional PA or AP-PA techniques: restoring an intermediate niche of therapeutic sophistication. Radiat Oncol (2013) 0.83
Modelling and dosimetry for alpha-particle therapy. Curr Radiopharm (2011) 0.81
Model development and use of ACE inhibitors for preclinical mitigation of radiation-induced injury to multiple organs. Radiat Res (2014) 0.81
Novel application of stereotactic ablative radiotherapy using CyberKnife(®) for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: Initial clinical experiences. Oncol Lett (2014) 0.80
Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate. EJNMMI Res (2016) 0.80
Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging (2017) 0.79
Double-arc volumetric modulated therapy improves dose distribution compared to static gantry IMRT and 3D conformal radiotherapy for adjuvant therapy of gastric cancer. Radiat Oncol (2015) 0.79
A Lipidomic and Metabolomic Serum Signature from Nonhuman Primates Exposed to Ionizing Radiation. Metabolomics (2016) 0.78
Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT/CT. Radiat Oncol (2014) 0.78
Radiobiological characterization of post-lumpectomy focal brachytherapy with lipid nanoparticle-carried radionuclides. Phys Med Biol (2011) 0.76
Pregnancy and Labor Complications in Female Survivors of Childhood Cancer: The British Childhood Cancer Survivor Study. J Natl Cancer Inst (2017) 0.75
Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma. Radiat Oncol (2016) 0.75
Attempted depletion of passenger leukocytes by irradiation in pigs. J Transplant (2011) 0.75
Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial. Radiat Oncol (2017) 0.75
Radiotherapy for gastric lymphoma: a planning study of 3D conformal radiotherapy, the half-beam method, and intensity-modulated radiotherapy. J Radiat Res (2014) 0.75
Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions. Can Urol Assoc J (2015) 0.75
Delayed renal dysfunction after total body irradiation in pediatric malignancies. J Radiat Res (2014) 0.75
A dose-volume intercomparison of volumetric-modulated arc therapy, 3D static conformal, and rotational conformal techniques for portal vein tumor thrombus in hepatocellular carcinoma. J Radiat Res (2013) 0.75
Predicting, preventing, treating and understanding radiation nephropathy. J Gastrointest Oncol (2010) 0.75
Radiotherapy of abdomen with precise renal assessment with SPECT/CT imaging (RAPRASI): design and methodology of a prospective trial to improve the understanding of kidney radiation dose response. BMC Cancer (2013) 0.75
Effect of Coenzyme Q10 on Radiation Nephropathy in Rats. J Korean Med Sci (2017) 0.75
Radiation-induced kidney injury. J Renal Inj Prev (2012) 0.75
Whole Abdominal-Pelvic Radiotherapy in the Management of Primary Ewing Sarcoma of the Peritoneal Cavity. Cureus (2016) 0.75
Basal renal function reserve and mean kidney dose predict future radiation-induced kidney injury in stomach cancer patients. Support Care Cancer (2013) 0.75
Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Res (2017) 0.75
Comparison of changes in renal function with dosimetric parameters in gastric cancer patients treated with adjuvant chemoradiotherapy. Jpn J Radiol (2017) 0.75
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol (2009) 4.59
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33
Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys (2002) 3.64
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys (2006) 3.40
High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys (2005) 3.32
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol (2009) 3.00
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol (2007) 2.80
Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys (2010) 2.69
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys (2003) 2.46
Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys (2003) 2.41
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys (2005) 2.41
Radiation-associated liver injury. Int J Radiat Oncol Biol Phys (2010) 2.39
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol (2005) 2.20
Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol (2004) 2.15
Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2009) 2.14
Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys (2010) 1.98
FDG-PET in radiotherapy treatment planning: Pandora's box? Int J Radiat Oncol Biol Phys (2004) 1.91
Accelerator beam data commissioning equipment and procedures: report of the TG-106 of the Therapy Physics Committee of the AAPM. Med Phys (2008) 1.89
Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer (2011) 1.87
Partial volume tolerance of the liver to radiation. Semin Radiat Oncol (2005) 1.85
The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys (2009) 1.69
The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer (2004) 1.67
Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys (2009) 1.64
Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. Phys Med Biol (2004) 1.63
Lymph node management in patients with paratesticular rhabdomyosarcoma: a population-based analysis. Cancer (2013) 1.55
Retrospective analysis of prostate cancer patients with implanted gold markers using off-line and adaptive therapy protocols. Int J Radiat Oncol Biol Phys (2005) 1.55
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol (2007) 1.55
The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys (2006) 1.52
Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys (2005) 1.49
The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol (2007) 1.49
Actual dose variation of parotid glands and spinal cord for nasopharyngeal cancer patients during radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.47
Predicting radiotherapy-induced cardiac perfusion defects. Med Phys (2005) 1.47
Prognostic factors in head and neck rhabdomyosarcoma. Head Neck (2002) 1.47
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol (2011) 1.46
Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys (2003) 1.45
Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. Int J Radiat Oncol Biol Phys (2010) 1.44
In vivo determination of extra-target doses received from serial tomotherapy. Radiother Oncol (2002) 1.42
Salvage intensity modulated radiotherapy using endorectal balloon after radical prostatectomy: clinical outcomes. Int J Urol (2013) 1.40
Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUD. Med Phys (2007) 1.40
CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan. Int J Radiat Oncol Biol Phys (2005) 1.38
Dose reconstruction in deforming lung anatomy: dose grid size effects and clinical implications. Med Phys (2005) 1.36
Tools for consensus analysis of experts' contours for radiotherapy structure definitions. Radiother Oncol (2010) 1.36
Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys (2002) 1.34
Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys (2011) 1.33
Presentation, prognostic factors and patterns of failure in adult rhabdomyosarcoma. Sarcoma (2003) 1.32
Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.32
Malignant phyllodes tumor of the breast: local control rates with surgery alone. Int J Radiat Oncol Biol Phys (2008) 1.32
Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys (2002) 1.28
Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg (2003) 1.28
Serial therapy-induced changes in tumor shape in cervical cancer and their impact on assessing tumor volume and treatment response. AJR Am J Roentgenol (2006) 1.28
Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis. Int J Radiat Oncol Biol Phys (2009) 1.25
Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys (2006) 1.24
A methodology for using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung. Int J Radiat Oncol Biol Phys (2006) 1.24
Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol (2011) 1.22
Evaluation of a commercial biologically based IMRT treatment planning system. Med Phys (2008) 1.22
Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys (2005) 1.22
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy. Radiat Oncol (2012) 1.21
Parotid gland function after radiotherapy: the combined michigan and utrecht experience. Int J Radiat Oncol Biol Phys (2010) 1.21
Methodological issues in radiation dose-volume outcome analyses: summary of a joint AAPM/NIH workshop. Med Phys (2002) 1.20
Guest editor's introduction to QUANTEC: a users guide. Int J Radiat Oncol Biol Phys (2010) 1.20
Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys (2005) 1.20
A region growing method for tumor volume segmentation on PET images for rectal and anal cancer patients. Med Phys (2009) 1.19
Simultaneous integrated boost for breast cancer using IMRT: a radiobiological and treatment planning study. Int J Radiat Oncol Biol Phys (2004) 1.19
Commissioning and clinical implementation of a mega-voltage cone beam CT system for treatment localization. Med Phys (2007) 1.19
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2008) 1.14
Direct aperture optimization-based intensity-modulated radiotherapy for whole breast irradiation. Int J Radiat Oncol Biol Phys (2007) 1.14
How extensive of a 4D dataset is needed to estimate cumulative dose distribution plan evaluation metrics in conformal lung therapy? Med Phys (2007) 1.13
A dose-volume-based tool for evaluating and ranking IMRT treatment plans. J Appl Clin Med Phys (2004) 1.12
Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys (2005) 1.11
Clinical implementation of intensity-modulated arc therapy. Int J Radiat Oncol Biol Phys (2002) 1.10
Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim (2007) 1.10
Physical models and simpler dosimetric descriptors of radiation late toxicity. Semin Radiat Oncol (2007) 1.10
The prediction of radiation-induced liver dysfunction using a local dose and regional venous perfusion model. Med Phys (2007) 1.09
Quality assurance for image-guided radiation therapy utilizing CT-based technologies: a report of the AAPM TG-179. Med Phys (2012) 1.09
Liver function after irradiation based on computed tomographic portal vein perfusion imaging. Int J Radiat Oncol Biol Phys (2007) 1.08
A method for incorporating organ motion due to breathing into 3D dose calculations in the liver: sensitivity to variations in motion. Med Phys (2003) 1.08
Evidence-based gallbladder cancer staging: changing cancer staging by analysis of data from the National Cancer Database. Ann Surg (2006) 1.08
Respiratory organ motion and dosimetric impact on breast and nodal irradiation. Int J Radiat Oncol Biol Phys (2010) 1.08
F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck (2005) 1.08
Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiother Oncol (2005) 1.08
Dosimetric and technical aspects of intraoperative I-125 brachytherapy for stage I non-small cell lung cancer. Phys Med Biol (2007) 1.07
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol (2009) 1.07
Toward a unified survival curve: in regard to Park et al. (IntJ Radiat Oncol Biol Phys 2008;70:847-852) and Krueger et al. (Int J Radiat Oncol Biol Phys 2007;69:1262-1271). Int J Radiat Oncol Biol Phys (2008) 1.07